Previous 10 | Next 10 |
Company to Provide Updates on Multiple Phase 2 Clinical Trials for GEO-CM04S1 and Gedeptin® ATLANTA, GA - ( NewMediaWire ) - August 31, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against c...
Seeking Improved Immune Response vs mRNA Vaccine Full Patient Enrollment Expected Within Six Months ATLANTA, GA - ( NewMediaWire ) - August 10, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and...
2023-08-09 20:18:07 ET GeoVax Labs, Inc. (GOVX) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Gabrielle DeGravina – Investor Relations-CG Capital David Dodd – Chairman and Chief Executive Officer Mark Reynolds ...
2023-08-09 17:37:22 ET GeoVax press release ( NASDAQ: GOVX ): Q2 GAAP EPS of -$0.22 misses by $0.05 . GeoVax reported cash balances of $17,788,911 at June 30, 2023, as compared to $27,612,732 at December 31, 2022. For further details see: GeoVax GAAP EPS of -...
Progress and Promising Outlook for Gedeptin ® and GEO-CM04S1; Phase 2 GEO-CM04S1; Clinical Trial Initiated for Patients with Chronic Lymphocytic Leukemia Company to H ost C onferen...
GeoVax to Host Second Quarter 2023 Conference Call at 4:30 PM ET ATLANTA, GA, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious ...
Addressing Multiple Strains of Ebolavirus ATLANTA, GA, July 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that th...
Seeking Improved Immune Response vs mRNA Vaccine ATLANTA, GA - ( NewMediaWire ) - July 20, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announce...
ATLANTA, GA - ( NewMediaWire ) - July 10, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the presentation of Phase 1/2 clinical trial data for GeoVax’s gene therapy ...
ATLANTA, GA, July 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the presentation of Phase 1/2 clinical trial data ...
News, Short Squeeze, Breakout and More Instantly...
ATLANTA, GA - ( NewMediaWire ) - July 11, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a cert...
GeoVax Labs, Inc. (NASDAQ: GOVX) is one of today's top gainers. The company's shares have moved 20.05% on the day to $3.02. GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ank...
Award of BARDA Project NextGen contract represents a significant milestone event; total value of award to GeoVax and its CRO partner total approximately $367-388 million BARDA-funded 10,000-participant Phase 2b study will evaluate and compare GeoVax’s ...